18. Oral colon cancer targeting by chitosan nanocomposites
Chitosan as anticancer drug for colon cancer treatment
Download 215.78 Kb.
|
bose2018
- Bu sahifa navigatsiya:
- Chitosan as drug carrier for colon cancer treatment
Chitosan as anticancer drug for colon cancer treatmentPrevious research and review articles report that chitin (N-acetyl-D-glucosamine oligomers) and chitosan (D-glucosamine oligosaccharide, COS) have anticancer properties. Chitosan can inhibit tumor cells directly by interfering cell metabolism, inhibiting cell growth, and inducing cell apoptosis. It also exhibits anticancer activ- ity through enhancing the body’s immune function. Several studies suggest that chitosan has antitumor effects in vitro and in vivo: Chitosan exhibits its chemo-preventive influence against colon cancer by increasing quinone reductase (QR) and glutathione S-transferases (GST) activities, and glutathione (GSH) con- centration by impeding ornithine decarboxylase (ODC) activity and cyclooxygenase-2 (COX-2) expression in vitro [8]. COS reduces pro-inflammatory cytokine-mediated nitric oxide (NO) synthesis, iNOS (inducible NO synthase) expression, and invasiveness of HT-29 cancer cell lines [9,10]. COS demonstrates antiangiogenic activity through inhibiting heparanase enzymatic activ- ity [11]. Chitosan and chitin induce lymphocyte cytokines through increased T-cell proliferation. Their antitumor activity is enhanced by acquired immunity through T-cell differentiation [12]. Low molecular weight chitosan is found to be more effective in cancer suppression than high molecular weight counterpart [13]. Table 18.1 summarizes the outcomes of experimental studies where chitosan is deemed to exhibit anticancer property. Chitosan as drug carrier for colon cancer treatmentNative chitosanNative chitosan has received widespread applications in designing nanoparticu- late drug delivery systems for cancer therapeutics. With reference to colonic tumor targeting, it can interact with anionic drugs to form complexes, protect the drugs from premature release at the upper gastrointestinal tract and has the drugs released specifically at the colon region via chitosan degradation through glycosidic linkage lysis by means of enzymatic actions of the colonic micro- flora [16]. Table 18.2 summarizes the outcome of experimental studies of native chito- san as a nanovehicle of anticancer therapeutics with respect to colon cancer treatment. Table 18.1 Experimental studies of chitosan as an anticancer drug
Table 18.2 Experimental studies of native chitosan as anticolon cancer drug nanocarrier
Download 215.78 Kb. Do'stlaringiz bilan baham: |
ma'muriyatiga murojaat qiling